Of note, although hyperkalemia has been described as an adverse outcome of the use of angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), two types of anti-hypertensive drugs, hypokalemia has also been described, particularly in those patients on dual therapy [15]. The gene discussed is ACE; the disease is Hyperkalemia.